Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

of this product franchise.

-- Sales of Sepra(R) products continued to be strong, rising 32 percent to

$30.6 million in the first quarter from $23.1 million in the same

quarter a year ago. The expanded U.S. sales force for Seprafilm(R)

adhesion barrier is reaching a broader range of physicians and helping

drive the product's growth in gynecologic and colorectal surgery.

Future growth of the product in C-section procedures and trauma

surgeries is expected.

-- First-quarter revenue for the Genetics business increased 12 percent to

$74.3 million from $66.2 million, fueled substantially by a higher

volume of reproductive diagnostic testing. The profitability of the

Genetics business is also increasing through improvements in operating

efficiencies, while Genzyme continues to invest in additional

information technology and infrastructure to strengthen the competitive

advantages the business has created. Genzyme Genetics recently

launched carrier and prenatal diagnostic testing for spinal muscular

atrophy, the most common inherited cause of infant mortality. These

tests are expected to support continued profitable growth in subsequent

quarters.

-- Oncology revenue increased 29 percent in the first quarter to $29.0

million from $22.4 million. This growth primarily reflects the

addition of European sales of Clolar, which Genzyme began recording

following its acquisition of Bioenvision Inc. late last year. Genzyme

is working to introduce Clolar worldwide through its global commercial

and regulatory organization. Oncology revenue also reflects growing

first-line use of Campath(R) (alemtuzumab) in the treatment of patients

with B-cell chronic lymphocytic leukemia.

Late-State Development Programs

Genzyme continues to make strong prog
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Spherix Incorporated (SPEX) ... fostering and monetization of intellectual property, today announced that ... period ending June 30, 2014 on Monday, August 18, ... at 10 a.m. ET on Monday, August 18, 2014 ... led by the company,s CEO, Anthony Hayes . ...
(Date:7/24/2014)... 2014 The patent provides substantially ... test results. It also enables true sample ID ... and reporting of high profile assays such as ... rapidly growing area of biotechnology that includes DNA ... and companion diagnostics in personalized medicine. The new ...
(Date:7/23/2014)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today ... For the second quarter ended June ... $7.0 million, or $0.10 per share, compared to a ... for the same period in 2013. As of June ... securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University ... have succeeded in embedding nearly perfect semiconductor crystals ... of producing hybrid nanowires, very fast and multi-functional ... chip in the future. The research results will ... . , Nano-optoelectronics are considered the cornerstone of ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9A crystal wedding in the nanocosmos 2
... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") ... ended March 31, 2010 . , ... "We have recently seen a range of ... mechanism of action and provided evidence of synergies with currently approved ...
... PARIS , May 12, 2010 , ... - New Outcomes Trial to Expand Evidence ... , ... of a multinational, randomized double-blind Phase IIIb trial,PALLAS, to assess the potential clinical benefit ...
... Scientists from Zymes LLC, the University of Windsor ... of Canada presented their research at the 2010 ... 28th .  The paper entitled, " Protection of SNpc neurons by ... disease: The role of neurotrophic factors," describes a potential treatment ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 2Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 3Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 4Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 5Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 6Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 7Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 8Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 2Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 4Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 5Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 6Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 7Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 8Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 10Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease 2
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... in which life arose have been maintained in our cells ... , Research published today in the Journal of Biological ... likely also in animals still perform ancient reactions thought to ... four billion years ago. , The primordial soup theory suggests ... result of the combination of metals, gases from the atmosphere ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Study gives new perspective on agricultural plastic, debris burning, and air quality 2Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... COLUMBIA Taking vitamin D supplements during pregnancy is not ... preterm labor/births and infections, according to results of a randomized ... (PAS) annual meeting in Vancouver, British Columbia, Canada. ... D could cause birth defects, according to Carol L. Wagner, ...
... UniversityCorpus Christi were astounded to find that seamounts, mountains that ... common ocean habitats in the world. Their findings are published ... prevalence of seamounts, which are treasure troves of marine biodiversity. ... never see a seamount, but this study shows that they ...
... of daily diet advice? If only we knew which ... new finding by a team of Cornell University researchers, dieters ... adhere to their diet. Understandably, they also report losing ... Brian Wansink, Director of the Cornell Food and Brand Lab, ...
Cached Biology News:Researchers recommend pregnant women take 4,000 IU vitamin D a day 2Scientists identify seamounts as significant, unexplored territory 2
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Biotin label transfer is fast emerging ... interaction discovery and confirmation. Until now, only ... targeted with label transfer reagents such as ... chain analog, Mts-Atf-LC-Biotin, are exciting additions to ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... fast emerging as a powerful new tool ... now, only amino groups have been able ... such as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and ... additions to the protein interaction tool chest ...
Biology Products: